,i #aadth ,,congress #ast ,session ,h4 ,r4 #bcch ,,in ,,the ,,house ,,of ,,representatives ,may #ad1 #bjae ,mr4 ,pitts introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act to provide for the development and use of patient experience data to enhance the structured risk-benefit assessment framework1 and for other purposes4 #a4 ,development and use of patient experience data to enhance structured risk-,benefit assessment framework 7a7 ,in general ,section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7 is amended-- 7#a7 in subsection 7d71 by striking ,the ,secretary shall implement and all that follows through premarket approval of a drug42 and 7#b7 by adding at the end the following new subsections3 7x7 ,structured risk-,benefit assessment framework 7#a7 ,in general ,the ,secretary shall implement a structured risk-benefit assessment framework in the new drug approval process-- 7,a7 to facilitate the balanced consideration of benefits and risks2 and 7,b7 to develop and implement a consistent and systematic approach to the discussion of1 regulatory decisionmaking with respect to1 and the communication of1 the benefits and risks of new drugs4 7#b7 ,rule of construction ,nothing in paragraph 7#a7 shall alter the criteria for evaluating an application for premarket approval of a drug4 7y7 ,development and use of patient experience data ,to enhance structured risk-,benefit assessment framework 7#a7 ,in general ,not later than two years after the date of the enactment of this subsection1 the ,secretary shall establish and implement processes under which-- 7,a7 an entity seeking to develop patient experience data may submit to the ,secretary-- 7i7 initial research concepts for feedback from the ,secretary2 and 7ii7 with respect to patient experience data collected by the entity1 draft guidance documents1 completed data1 and summaries and analyses of such data2 7,b7 the ,secretary may request such an entity to submit such documents1 data1 and summaries and analyses2 and 7,c7 patient experience data may be developed and used to enhance the structured risk-benefit assessment framework under subsection 7x74 7#b7 ,patient experience data ,in this subsection1 the term patient experience data means data collected by patients1 parents1 caregivers1 patient advocacy organizations1 disease research foundations1 medical researchers1 research sponsors or other parties determined appropriate by the ,secretary that is intended to facilitate or enhance the ,secretary's risk-benefit assessments1 including information about the impact of a disease or a therapy on patients' lives4 4 7b7 ,guidance 7#a7 ,in general ,the ,secretary of ,health and ,human ,services shall publish guidance on the implementation of subsection 7y7 of section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee71 as added by subsection 7a74 ,such guidance shall include-- 7,a7 with respect to draft guidance documents1 data1 or summaries and analyses submitted to the ,secretary under paragraph 7#a77;,a7 of such subsection1 guidance-- 7i7 specifying the timelines for the review of such documents1 data1 or summaries and analyses by the ,secretary2 and 7ii7 on how the ,secretary will use such documents1 data1 or summaries and analyses to update any guidance documents published under this subsection or publish new guidance2 7,b7 with respect to the collection and analysis of patient experience data 7as defined in paragraph 7#b7 of such subsection 7y771 guidance on-- 7i7 methodological considerations for the collection of patient experience data1 which may include structured approaches to gathering information on-- 7,i7 the experience of a patient living with a particular disease2 7,,ii7 the burden of living with or managing the disease2 7,,iii7 the impact of the disease on daily life and long-term functioning2 and 7,,iv7 the effect of current therapeutic options on different aspects of the disease2 and 7ii7 the establishment and maintenance of registries designed to increase understanding of the natural history of a disease2 7,c7 methodological approaches that may be used to assess patients' beliefs with respect to the benefits and risks in the management of the patient's disease2 and 7,d7 methodologies1 standards1 and potential experimental designs for patient-reported outcomes4 7#b7 ,timing ,not later than three years after the date of the enactment of this ,act1 the ,secretary of ,health and ,human ,services shall issue draft guidance on the implementation of subsection 7y7 of section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee71 as added by subsection 7a74 ,the ,secretary shall issue final guidance on the implementation of such subsection not later than one year after the date on which the comment period for the draft guidance closes4 7#c7 ,workshops 7,a7 ,in general ,not later than #f months after the date of the enactment of this ,act and once every #f months during the following #ab-month period1 the ,secretary of ,health and ,human ,services shall convene a workshop to obtain input regarding methodologies for developing the guidance under paragraph 7#a71 including the collection of patient experience data4 7,b7 ,attendees ,a workshop convened under this paragraph shall include-- 7i7 patients2 7ii7 representatives from patient advocacy organizations1 biopharmaceutical companies1 and disease research foundations2 7iii7 representatives of the reviewing divisions of the ,food and ,drug ,administration2 and 7iv7 methodological experts with significant expertise in patient experience data4 7#d7 ,public meeting ,not later than #ij days after the date on which the draft guidance is published under this subsection1 the ,secretary of ,health and ,human ,services shall convene a public meeting to solicit input on the guidance4